ENTA—After listening to the CC and further contemplating the EDP-305 dataset reported today, I think ENTA should strongly consider switching from EDP-305 to the company's backup FXR compound.
EDP-305's pruritis rate at 2.5mg is too high, and it's unclear whether there's a bona fide therapeutic window for this drug.
Market Data 
Markets 
AI
